ClinicalTrials.gg
SuspendedNCT05958199Updated Jun 27, 2025

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

A Phase 1 interventional study of NPX267 in Metastatic Malignant Neoplasm, sponsored by NextPoint Therapeutics, Inc.. Suspended at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by NextPoint Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was suspended
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
426th of 1,866
131 · median 43
Started
2023
with 101 others
Phase 1
710 of 2,057
127 open now
Registered
1,797th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 426th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 102 that started in 2023, is one of 710 in phase 1, and was the 1,797th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are:

  • what is an appropriate dose to be given to patients?
  • are the side effects of treatment manageable?

Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.

Read the detailed description

This trial is divided into two parts. The first part (dose escalation) will test different doses of drug to find a dose for part two. In the second part (dose expansion), more patients will be tested to see if the drug has an effect on patient's tumors.

Throughout the study, data will be collected to characterize the clinical activity of the drug. Samples of blood will be taken to help in an understanding of how the drug behaves in the body by assessing the amount of drug in the blood over time (pharmacokinetics), and changes in blood components (pharmacodynamics and safety). Tumor imaging by computed tomography (CT) or magnetic resonance imaging (MRI) will be done about every nine weeks to assess NPX267 impact on tumor growth.

03

Conditions studied

  • Metastatic Malignant Neoplasm

Keywords

  • B7-H7/HHLA2
  • Non-small cell lung carcinoma
  • renal cell carcinoma
  • colorectal carcinoma
  • cholangiocarcinoma
  • pancreatic cancer
  • urothelial carcinoma
  • gastric gastroesophageal carcinoma
  • triple negative breast carcinoma
  • endometrial carcinoma
  • cervical cancer
  • osteosarcoma
  • prostate cancer
  • RECIST
  • Dose escalation
  • Dose expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed recurrent, solid tumor to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer
  • (ECOG) performance status 0 or 1
  • Normal bone marrow, kidney and liver function
  • Willing to use highly effective measures throughout the trial

Exclusion criteria

Exclusion Criteria:

  • Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy > 6 months, or changes in skin pigmentation
  • Have known or suspected , unless they are clinically stable
  • Known disease requiring treatment requiring the equivalent of more than 10 mg prednisone daily
  • History of grade 3 immune-related pneumonitis or colitis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (estimated)

Study arms

  • Experimental
    NPX267 Treatment

    Drug: NPX267

Interventions

  • DrugNPX267

    NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity

    Number of subjects with dose limiting toxicity

    Time frame: from first dose through 21 days

  2. Incidence of treatment-emergent adverse events

    Number and type of adverse events categorized by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: up to 12 weeks from first dose

  3. Number of subjects with tumor response in tumors expressing B7-H7/HHLA2

    The proportion of subjects with complete or partial responses or stable disease as defined by RECIST 1.1 criteria

    Time frame: up to 12 weeks from first dose

Secondary outcomes

  1. Area under the concentration curve (AUC) of NPX267

    Measurement of plasma concentration over time for exposure to NPX267

    Time frame: Following dosing on day 1, day 22, and day 43 (day 1 of 21-day treatment cycles)

  2. Half-life in circulation (T1/2) of NPX267

    Measurement of the clearance of NPX267 from plasma over time

    Time frame: Following dosing on day 1, day 22, and day 43 (day 1 of 21-day treatment cycles)

  3. Maximum plasma concentration (Cmax) of NPX267

    Time frame: Following dosing on day 1, day 22, and day 43 (day 1 of 21-day treatment cycles)

  4. Overall survival

    Average length of survival for treated patients

    Time frame: From first dose until death from any cause through 30 months

  5. Immunogenicity of NPX267

    Number of participants with anti-drug antibodies

    Time frame: From first dose through one year

Other outcomes

  1. Change in biomarkers of activity

    Exploratory analysis of biomarkers from collected tumor and blood samples

    Time frame: From first dose through one year

07

Study locations

7 sites
  • Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Albert Einstein Medical College Montefiore Medical Center
    New York, New York 10461, United States
  • Sarah Cannon Research Institute Oncology Partners
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology-San Antonio
    San Antonio, Texas 78229, United States
  • NEXT Oncology-Fairfax
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Sep 2025, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2023
First posted
Jul 24, 2023
StartActual
Jul 21, 2023
Primary completionEst.
Sep 20, 2025
CompletionEst.
Sep 20, 2025
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958199
Lead sponsor
NextPoint Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2023
Start date
Jul 21, 2023
Primary completion
Sep 20, 2025 (estimated)
Completion
Sep 20, 2025 (estimated)
Last update
Jun 27, 2025

Study contacts

Leena Gandhi, MD, PhD
study director · NextPoint

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion